Get the Stockscreener App
4.06
0.98%
-0.04
After Hours:
4.06
Orchestra Biomed Holdings Inc stock is traded at $4.06, with a volume of 198.27K.
It is down -0.98% in the last 24 hours and down -3.56% over the past month.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
See More
Previous Close:
$4.10
Open:
$4.12
24h Volume:
198.27K
Relative Volume:
0.89
Market Cap:
$243.12M
Revenue:
$33.48M
Net Income/Loss:
$-52.70M
P/E Ratio:
-3.15
EPS:
-1.2889
Net Cash Flow:
$-49.45M
1W Performance:
+9.14%
1M Performance:
-3.56%
6M Performance:
-10.38%
1Y Performance:
+48.72%
1-Day Range:
$4.05
$4.135
1-Week Range:
$3.75
$4.155
52-Week Range:
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.06 | 245.51M | 33.48M | -52.70M | -49.45M | -1.2889 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
OBIO Q1 2026 Earnings: Narrowed Loss as EPS Surpasses Estimates; Stock Posts Modest DeclineHot Market Picks - Newser
Orchestra BioMed Advances FDA Path for Hypertension Device - MyChesCo
Orchestra BioMed Targets 2027 Data for Hypertension Trial - MyChesCo
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
Orchestra BioMed director Jason buys $2,493 in stock - Investing.com UK
Orchestra BioMed director Jason buys $2,493 in stock By Investing.com - Investing.com Canada
Orchestra BioMed (OBIO) director adds 665 shares in open-market buy - Stock Titan
Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68 - MSN
Orchestra BioMed CEO David Hochman buys $18,850 in company stock By Investing.com - Investing.com Nigeria
Orchestra BioMed director Aryeh Jason buys $34,986 in stock By Investing.com - Investing.com Nigeria
Orchestra BioMed CEO David Hochman buys $18,850 in company stock - Investing.com India
Jefferies healthcare fireside chat to feature Orchestra BioMed CEO - Stock Titan
Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market - Stock Titan
Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy - Stock Titan
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating - marketscreener.com
Orchestra BioMed director Fain buys $82,600 in shares By Investing.com - Investing.com South Africa
Orchestra BioMed director Fain buys $82,600 in shares - Investing.com UK
Orchestra BioMed (OBIO) director trust buys 20,000 shares - Stock Titan
Orchestra BioMed Holdings, Inc. (OBIO) reports Q1 loss, lags revenue estimates - MSN
Orchestra BioMed Secures Ligand Funding for Pivotal Trials - MyChesCo
H.C. Wainwright Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial - MyChesCo
Orchestra BioMed Holdings (OBIO) Receives a Buy from H.C. Wainwright - The Globe and Mail
OBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.57, Implies 210% Upside - TradingView
Orchestra BioMed Q1 Loss Narrows, Revenue Falls - Moomoo
TradingKey - TradingKey
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Investing News Network
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Orchestra BioMed Holdings, Inc._March 31, 2026 - SEC.gov
Press Release: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Moomoo
Orchestra BioMed (NASDAQ: OBIO) Q1 2026 loss, cash and funding update - Stock Titan
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 - Investing News Network
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial By Investing.com - Investing.com Australia
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial - Investing.com
Orchestra Biomed Holdings Announces Update on Backbeat Global Pivotal Trial Timeline - marketscreener.com
Why Orchestra (OBIO) might be the best kept secret in the market (Grinds Higher) 2026-05-08Stock Idea Sharing Hub - newser.com
U.S. Earnings Preview: After Market Close May 8 - Moomoo
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orchestra Biomed Holdings Inc Stock (OBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aryeh Jason | Director |
May 15 '26 |
Buy |
3.90 |
8,971 |
34,987 |
117,453 |
| Hochman David P | See Remarks |
May 15 '26 |
Buy |
3.77 |
5,000 |
18,850 |
1,059,029 |
| Fain Eric S | Director |
May 14 '26 |
Buy |
4.13 |
20,000 |
82,600 |
91,709 |
| RTW INVESTMENTS, LP | 10% Owner |
Apr 27 '26 |
Sale |
4.13 |
32 |
132 |
9,556,063 |
| Hochman David P | See Remarks |
Mar 13 '26 |
Buy |
4.29 |
10,000 |
42,900 |
1,086,467 |
| Hochman David P | See Remarks |
Nov 14 '25 |
Buy |
4.07 |
5,000 |
20,350 |
612,822 |
| Aryeh Jason | Director |
Sep 19 '25 |
Buy |
2.45 |
1,000 |
2,450 |
108,482 |
| Fain Eric S | Director |
Aug 25 '25 |
Buy |
2.61 |
5,760 |
15,034 |
71,709 |
| Sherman Darren | See Remarks |
Aug 25 '25 |
Buy |
2.62 |
3,000 |
7,860 |
926,837 |
| Hochman David P | See Remarks |
Aug 21 '25 |
Buy |
2.49 |
6,000 |
14,940 |
651,460 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):